Clearmind Medicine Inc.
CMND evidence brief
What we can confirm
- Market Cap:
- $1.4M
What it means
What to watch
Prepared research question
What matters most for CMND—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CMND
Clearmind Medicine Inc. (CMND) is a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders, with its lead candidate CMND-100 currently in Phase I/IIa trials for Alcohol Use Disorder.
Key risk: Early-stage clinical risk
Market Cap
$1.4M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for Clearmind Medicine Inc..
Clearmind Medicine Inc. (CMND) is a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders, with its lead candidate CMND-100 currently in Phase I/IIa trials for Alcohol Use Disorder.
- Lead candidate CMND-100 is a non-hallucinogenic MEAI-based oral drug being evaluated in a Phase I/IIa clinical trial for Alcohol Use Disorder [news].
- The company completed dosing for all 24 participants in Part A of its Phase I/II trial as of June 2026 [news].
- Clearmind received DSMB approval to advance CMND-100 to AUD patients after achieving the primary safety endpoint [news].
- As of January 31, 2026, the company reported cash & equivalents of $9.3M and a net loss of -$3.9M [sec].
- The company has secured IRB approvals from Johns Hopkins and Yale for advancing the trial to Parts B and C [news].
What works
- CMND-100 has successfully completed Part A dosing and achieved its primary safety endpoint, allowing progression to patient enrollment for AUD [news].
- The drug is designed as a non-hallucinogenic neuroplastogen, which may offer a scalable treatment advantage over classic psychedelics [news].
- Clearmind has secured IRB approvals from both Johns Hopkins and Yale, enabling multi-site patient recruitment for Parts B and C [news].
What to weigh
- The company reported a net loss of -$3.9M as of January 31, 2026, indicating ongoing cash burn without approved product revenue [sec].
- CMND-100 is still in early clinical stages (Phase I/IIa), with no completed efficacy data or regulatory approval for AUD [news].
- Cash & equivalents of $9.3M as of January 31, 2026 may limit the runway for completing the full Phase I/IIa trial without additional financing [sec].
From the filings
Quoted directly from source documents.
CMND-100 completed Part A dosing for all 24 participants.
“successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A”
News · June 16, 2026
DSMB approved advancement to AUD patients after safety endpoint was met.
“Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD)”
News · August 13, 2026
Yale IRB approved patient recruitment for Parts B and C.
“Yale University’s IRB has approved the initiation of patient recruitment for Parts B and C of its Phase I/II clinical trial”
News · September 8, 2026
Risks & what to watch (3)›
Key risks
- Early-stage clinical risk — CMND-100 is only in Phase I/IIa; no completed efficacy data or regulatory approval for AUD exists [news].
- Cash runway constraint — Cash & equivalents of $9.3M as of Jan 31, 2026 may be insufficient to complete the trial without additional funding [sec].
- Net loss accumulation — Net loss of -$3.9M as of Jan 31, 2026 indicates ongoing operating losses without revenue [sec].
What to watch
- Completion of patient enrollment and dosing for Parts B and C of the CMND-100 Phase I/IIa trial [news].
- Release of interim efficacy data from the ongoing AUD trial [news].
- Any new financing or partnership announcements given the current cash position [sec].
- Regulatory milestones such as FDA feedback or potential breakthrough designation [news].
Sources: News · Generated October 2, 2026 · How we verify sources →
Run Clearmind Medicine Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Clearmind Medicine Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$30K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 21,694 | $23K |
| advisorshares investments llc | 7,357 | $8K |
| hrt financial lp | 15,910 | $16 |
| ubs group ag | 1 | $1 |
| royal bank of canada | 14 | $0 |
Short Interest
as of May 20, 2026- % of float
- 4.3%
- Days to cover
- 0.0
- Shares short
- 437,078
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CMND short interestFrequently asked questions
What is the AI investment thesis for Clearmind Medicine Inc.?
Clearmind Medicine Inc. (CMND) is a clinical-stage biopharmaceutical company developing non-hallucinogenic, psychedelic-derived neuroplastogens for neuropsychiatric, metabolic, and addiction disorders, with its lead candidate CMND-100 currently in Phase I/IIa trials for Alcohol Use Disorder.
Who is the CEO of Clearmind Medicine Inc.?
Dr. Adi Zuloff-Shani Ph.D. is the chief executive officer of Clearmind Medicine Inc. (CMND).
Where is Clearmind Medicine Inc. headquartered?
Clearmind Medicine Inc. (CMND) is headquartered in Vancouver, BC, Canada.
What therapeutic areas does Clearmind Medicine Inc. focus on?
Clearmind Medicine Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.